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http://www.biomedcentral.com/1472-6963/14/514RESEARCH ARTICLE Open AccessDirect costs of hypertensive patients admitted
to hospital in Vietnam– a bottom-up
micro-costing analysis
Thi-Phuong-Lan Nguyen1*, Thi Bach Yen Nguyen2, Thanh Trung Nguyen3,4, Van Vinh Hac4, Hoa H Le1,
CCM Schuiling-Veninga1 and Maarten J Postma1,5Abstract
Background: There is an economic burden associated with hypertension both worldwide and in Vietnam. In
Vietnam, patients with uncontrolled high blood pressure are hospitalized for further diagnosis and initiation of
treatment. Because there is no evidence on costs of inpatient care for hypertensive patients available yet to inform
policy makers, health insurance and hospitals, this study aims to quantify direct costs of inpatient care for these
patients in Vietnam.
Methods: A retrospective study was conducted in a hospital in Vietnam. Direct costs were analyzed from the
health-care provider’s perspective. Hospital-based costing was performed using both bottom-up and micro-costing
methods. Patients with sole essential or primary hypertension (ICD-code I10) and those comorbid with sphingolipid
metabolism or other lipid storage disorders (ICD-code E75) were selected. Costs were quantified based on financial
and other records of the hospital. Total cost per patient resulted from an aggregation of laboratory test costs, drug
costs, inpatient-days’ costs and other remaining costs, including appropriate allocation of overheads. Both mean
and medians, as well as interquartile ranges (IQRs) were calculated. In addition to a base-case analysis, specific
scenarios were analyzed.
Results: 230 patients were included in the study (147 cases with I10 code only and 83 cases with I10 combined
with E75). Median length of hospital stay was 6 days. Median total direct costs per patient were US$65 (IQR: 37 -95).
Total costs per patient were higher in the combined hypertensive and lipid population than in the sole hypertensive
population at US$78 and US$53, respectively. In all scenarios, hospital inpatient days’ costs were identified as the major
cost driver in the total costs.
Conclusions: Costs of hospitalization of hypertensive patients is relatively high compared to annual medication
treatment at a community health station for hypertension as well as to the total health expenditure per capita in
Vietnam. Given that untreated/undetected hypertension likely leads to more expensive treatments of complications,
these findings may justify investments by the Vietnamese health-care sector to control high blood pressure in order to
save downstream health care budgets.
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Hypertension represents a health and economic burden
worldwide. In 2000, approximately one quarter of the
adult populations had hypertension, equaling to approxi-
mately 972 million adults [1]. Furthermore, it has been
projected that almost 30% of the world’s adult popula-
tion will be hypertensive by 2025 [1]. High blood pres-
sure and associated diseases may be responsible for up
to 7 million deaths annually worldwide [2]. In the Eastern
European and Central Asian regions, high blood pressure
is estimated to directly or indirectly account for 25% of all
health expenditures [3]. In Southwest China, a cost-of-
illness analysis from the societal perspective in 2010 esti-
mated the cost of hypertension to be US$9,393 per patient
[4]. In the Philippines, a health insurance company re-
ported reimbursement for hypertension- related diagnoses
during 3.5 years to be US$56 million for 360,016 patients
[5]. This equals to 34% of their financial budget for hos-
pital spending [5].
Among the group of developing countries, the preva-
lence of hypertension in Vietnam can be rated as inter-
mediate with estimates ranging from 20% to 30% in
adults [6]. In recent years, hypertension has been one of
the main contributors to the overall burden of disease in
Vietnam [7,8]. A national survey, conducted between
2002 and 2008, estimated prevalence rates for overall,
male, and female populations to be 25.1%, 28.3% and
23.1%, respectively [8]. Using the Framingham general
cardiovascular risk score, it was estimated that the
prevalence of people with overall 10-year cardiovascular
disease (CVD) risks ≥10%, 20% and 30% are 27%, 10%
and 3.9%, respectively [9,10] For patients who are 60-
and-above years old, hypertension as the underlying
cause of death ranks third for males (6.2% of all deaths)
and second for females (6.6% of all deaths). For all ages,
hypertension ranks sixth for males (3.8% of all deaths)
and second for females (5.1% of all deaths) [7]. Treat-
ment of hypertension is crucial to avert these high risks,
associated costs and related deaths.
Compared to surrounding countries, hypertension
may impact even higher costs to society in Vietnam be-
cause diagnosis and initiation of treatments for hyper-
tension often take place in the hospital. This may be
explained by several factors, including the absence of
some specific services in primary care for all regions of
the country, the perception that hospital care offers a
higher quality of care and the preference for specific ser-
vices to be in a hospital setting for administrative and
convenience reasons. At present, the inpatient and out-
patient economic burdens of hypertension in Vietnam
have not been estimated precisely. In addition, studies
on the topic are scarce. One study at the community-
health station level on the cost of drug treatment for thewhole population over a 10-years period estimated costs
of 9,808 billion VND associated with grade 1 hyperten-
sion and 11,192 billion VND associated with grade 2
and 3 hypertension [11]. The sum of these figures repre-
sent approximately 14% of the total health expenditure
in 2010 [12,13]. Notably, among hypertensive patients,
only 29.6% was treated and 10.7% achieved target blood
pressure control [8]. Patients, who are not treated and
have uncontrolled high blood pressure, are at higher
risks of complications requiring hospitalization, which
add to the economic burdens for the health care system.
The health-care provider payment system in Vietnam
is currently being reformed. The fee- for-service system
will be replaced by case-mix payments and eventually
diagnostic-related groups [14]. Thus, to support reim-
bursement decisions based on diagnostic-related groups,
it would be useful for the Vietnamese health insurance
system to have accurate estimates of costs associated
with hypertension.
In addition, hospitals in Vietnam are gaining greater au-
tonomy. Having knowledge on their expenditures for in-
patient care services will help these hospitals to improve
their financial management as well as to adequately issue
fees for both insured and non-insured patients. Currently,
neither information on the costs of inpatient care for the
treatment of hypertension and its consequences nor solid
estimates on the comprehensive costs of hypertension
management is available in Vietnam.
To address these gaps of information, we conducted
this study to quantify the direct costs of inpatient care
for hypertensive patients. Furthermore, these results may
1) contribute to a better understanding of the economic
burden of hypertension in Vietnam, 2) help with reim-
bursement decision making for insured patients, 3) sup-
port setting potential fees and charges to be issued for
non-insured patients and 4) inform on potential impacts
of preventive policies.Methods
Study design and setting
We conducted a retrospective study in the Thai
Nguyen hospital. Data was collected from the financial
records during October 1st 2010 to September 30th
2011.
The study was conducted at a regional hospital with
800 beds in the city of Thai Nguyen, which is located in
a mountainous area that is approximately 100 km North
of Hanoi. It serves patients from Thai Nguyen and neigh-
boring provinces.
All costing of resource utilization was adjusted to
2011 levels and presented in US$ using the exchange rate
of US$1 to VND20.830 [15].
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Using the International Classification of Diseases 10th
version (ICD-10), we identified and retrieved informa-
tion on all patients with codes I10 alone (essential or
primary hypertension) or comorbid patients with I10
combined with E75 (sphingolipid metabolism and
other lipid storage disorders). The latter group was
included because hypertension often coincides with
these disorders. The combination of diagnoses might
reflect a relatively large share of the overall hyperten-
sive patient group with deviating costs. ICD-10 codes
were taken from hospital databases and individual pa-
tients’ records.
Information on age, sex and ICD code was available
for all of the selected patients with ICD code I10 or I10
combined with E75.
However, data might be missing as administrators
may forget to enter classification data or misclassify;
i.e. patients and/or patient-related data might be miss-
ing. In addition, by doing this retrospectively, we had
no certainty on whether each financial record was in-
cluded or not. Nurses should enter all consumed items
such as drugs, tests, medical materials into the data-
base system before she/he can get them from store or
lab services. Other cost items such as patient-days and
examinations were automatically recorded for every pa-
tient. This ensures that all these items were recorded
and financial records are likely complete. Whenever fi-
nancial records seemed grossly incomplete or absent at
all, patients were excluded. This was however not the
case. It was therefore plausibly assumed that missing
data was limited and random. Thus, no specific bias
was expected.Costing perspective and cost components
Direct costs were analyzed from the provider perspec-
tive. Data on costs included all charges to patients for
drugs, materials (both medical and non-medical) and
laboratory testing, all crucial elements in the financial
records and reflecting adequate charging. In particular,
hospital-based costing was performed using both bottom-
up and micro-costing methods and aggregation was subse-
quently conducted for all costs related to medical services
used by a group of hospitalized patients [16,17]. For this
purpose, costs of inpatient care were broken down into
two parts:Inpatient – day costs ¼ Total costs a given dep
total number of patient‐days atInpatient – days costs and other costs (laboratory test-
ing, drugs, medical materials charged to patients directly,
admission, and examinations by specialists). Costs of in-
patient care can be expressed as:
Costs of inpatient care ¼ inpatient‐days costs
þ laboratory test costs
þ drug costs þ costs of
medical materials charged
to patients directly
þ admission costþ costs of
examinations by specialists
Method of cost measurements
Calculation of inpatient – days’ costs
The step-down allocation method- partially adjusted for
interaction between overhead departments- was applied
for allocating overhead costs [17]. In the base-case, the
discount rate for medical equipment and building was
3% [17]. The formula applied here may be expressed as:
Total costs of each department
¼ total labor costs þ total costs of materials=
infrastructure ðboth medical and non‐medical;
not charged to patients directlyÞ þ total costs
of capital ðboth medical and non‐medical
equipment and buildingsÞ
Labor costs were calculated based on the actual pay-
ment for labor by the hospital every month during a
year; funding was provided by government or specific
funds for services organized by the hospital. Material/in-
frastructure costs were calculated by items used at each
department multiplied with the price market which the
hospital paid based on again monthly updated records of
the hospital. Capital costs were calculated based on as-
sets’ records of the hospital, which is updated every year.
Notably, non-medical costs of materials/infrastructure
primarily comprise of power, telephone, uniforms, sta-
tionary and cloths. In the absence of any detailed infor-
mation, an assumption was made that equal costs for an
inpatient day would apply for every disease within each
department.
The inpatient–day costs per department resulted from
the total costs divided by the total number of inpatient
days for that department:artment
that department
Nguyen et al. BMC Health Services Research 2014, 14:514 Page 4 of 8
http://www.biomedcentral.com/1472-6963/14/514Other costs and total patient costs
The cost-to-charge ratio method was applied to calcu-
late laboratory testing costs [17]. While the input data
to calculate cost of each test - such as number of che-
micals used, time investment of staff members to run
each test, etcetera - were limited, total input of each
department, total number of tests per type and prices
were available. Therefore, cost-to-charge ratio was con-
sidered to be the best method for calculating labora-
tory costs. At each laboratory department, we tracked
the number of each test and multiplied these by the
charges that apply in the hospital (base on the recom-
mendation of the Ministry of Health). We subsequently
summed up all those items to identify total finances of
that department. Cost-to-charge ratio in each depart-
ment was calculated dividing total input costs of each
department in terms of building, labor, material, equip-
ment, etcetera by those total finances generated through
charges. Information on numbers of test was only available
for the last half of the year because of a mistake in the
software to extract total number of each test. To
annualize, the total numbers for each test was multiplied
by two.
In this study, standard national prices for drugs and
materials were not available. As Thai Nguyen hospital is
a non-profit hospital, we assumed that the use of drug
and material charges from this hospital would well ap-
proach actual costs. Cost of drugs and materials were
calculated based on the current market prices, which the
hospital paid. Therefore, we could validly impute these
charges into our cost analysis for each drug and material
used [17]. Both drugs and medical materials were charged
to patients directly and accordingly inserted in the ana-
lysis. These costs were consistently calculated based on
numbers of items used multiplied by the specific prices of
each item.
Admission cost, which is required for every intake
examination for admission to the hospital, was calcu-
lated similarly as was done for inpatient – day’ costs. Ad-
mission costs per patient is equal to the total costs of
outpatient department divided by the total number pa-
tient visits at outpatient.
Examination costs at specialist departments were cal-
culated for patients who had specific examinations. Ex-
aminations were counted and monetized using charges
as determined by the recommendations of the Ministry
of Health.
Total costs per patient resulted from the aggrega-
tion of inpatient-days’ costs multiplied by the length
of stay, laboratory test costs, drug costs, medical ma-
terial costs, admission costs, and costs of examina-
tions at specialist departments. Example of calculating
total costs for a patient is presented in the Additional
file 1.Sources of data
Labor costs (wages and allowances) were quantified
based on financial records of the hospital. Material (not
charged to patients directly) and capital (both medical
and non-medical equipment and building costs) were
quantified based on the financial records, administra-
tion of materials used and capital inventories of the
hospital.
Age, sex, department, length of stay, total numbers of
each laboratory test, numbers of each drug and medical
materials charged to patients directly were retrieved
from patient-based databases of the hospital. Prices for
specific services such as medication, materials/dispos-
ables and laboratory tests were available from the spe-
cific databases of the hospital. Furniture and land costs
were not included in this study as no information was
available.
The number of tests completed for each patient and
its charges were obtained from the individual patient
sheets. We selected all tests, including test for the diag-
nosis and/or treatment of hypertension and other con-
dition. Total number of all tests in 6 months was
multiplied by 2 and then divided by the total number of
patients in 2011, equating 11 in the whole hospital. For
the hypertensive in-patient group, the average number
of tests per patient was 16.8, 16.3 and 17.1 in both
groups, I10 and I10 + E75, respectively. Of course for
costing, each individual test was priced separately.
Statistical and sensitivity analysis
Means, medians and Inter Quartile Range (IQRs) of
costs were measured as outcome in this study. Uni-
variate sensitivity analyses were performed to explore
the robustness of the analyses [18]. Notably, hyper-
tensive patients may be admitted to hospital with
comorbidities.
In this context, it is very important to rule out the
costs resulting from diagnosing and treating these other
diseases. Therefore, we conducted one sensitivity ana-
lysis with a scenario that excluded all costs resulting
from diagnosing and treating comorbid diseases. We
limited to specific costs for diagnosing and treating I10
and E75 diseases in this scenario. In addition, the dis-
count rate for capital was varied from 1% to 5%. As data
on furniture were not available, these costs were not in-
cluded in the base case. Additionally, a scenario where
an estimated 5% furniture cost was added to the total
capital cost was explored [19]. Finally and in the absence
of standardized national prices, we analyzed sensitivity t
o laboratory tests by using laboratory test charges in-
stead of laboratory test costs as used in the base case.
Multivariate sensitivity analyses were also performed to
explore the contribution of two or three parameters at
once to the uncertainty in the total costs.
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This study was approved by the ethical committee of the
Thai Nguyen General hospital. Databases of this study
were used under the permission of the Planning depart-
ment of the Thai Nguyen General hospital.
Results
The analyses were based on 230 patients who met the
inclusion criteria, including 147 cases with essential
(primary) hypertension (I10) and 83 cases with hyper-
tension combined with sphingolipid metabolism and
other lipid storage disorders (I10 + E75). Mean age was
64.3 (SD +/-14.7) and 53.5% was female. Characteristics
of patients are indicated in Table 1. Median length of
stay was 6 days with an IQR of 3-8 in the whole study
population, and 5 days (IQR: 2-7) and 7 days (IQR: 5-9)
in the in the I10 and I10 + E75 groups, respectively.
Hypertensive patients were admitted in 3 departments
of the hospital; i.e., Cardiovascular Internal Medicine,
Geriatric Internal Medicine and Neurology. For these
departments, base- case inpatient– day costs were US
$4.99, US$5.05 and US$5.33, respectively. Notably, the
most expensive per day costs were associated with pa-
tients admitted to Neurology department.
Costs of treatment for these hypertensive inpatients
are presented in Table 2 as the result of the base case,
which considers a 3% discount, uses laboratory test
charges and includes no furniture costs. Median total
direct costs per patient were US$65 (IQR: 37-95). Total
costs per patient were higher in the combined hyper-
tensive and lipid population (US$78) than in the sole
hypertensive patients (US$53). However, the median
costs per day were slightly higher in the sole hyperten-
sive patients compared to the combined group with es-
timates of US$11.4 and US$10.9, respectively. In the
base-case, inpatient-day costs, at 41% of the total cost,
represented the highest cost component. Costs of drugs
followed as second largest cost component with 34%, as
presented in Table 2.
Results of the sensitivity analyses, including 12 scenar-
ios reflecting relevant alternative options, are presented
in Figure 1. In all scenarios, inpatient-day costs appearedTable 1 Characteristic of patients






I10 + E75 83 36%
Age (mean ± SD) 64.3 (±14.7)to be the most important cost driver in the total costs
per patient. In the scenario where costs of comorbid dis-
eases were excluded, the median total direct costs per
patient were US$64.6 (IQR: 37 -95). Using laboratory
testing charges instead of costs showed changes in the
specific scenarios with increases between 15% and 17%
(or US$75 to US$76 for total cost) compared to the
base-case. Other scenarios, such as changing discount
rates to 1% and 5%, adding 5% furniture to the capital
costs produced minor impact on the total costs (from
minus 0.8% to 1.1% changes in total costs).
Discussion
Hypertension is a major and increasing public health
problem in Vietnam, including 5.7 million patients un-
aware of their status, 2.1 million aware but untreated,
2.0 million treated but uncontrolled and 1.2 million
treated and controlled [8]. Notably, the proportion of pa-
tients treated and controlled is modest, illustrating a po-
tential for improvement. Vietnam spends huge amounts
of money on these groups, especially when they need
hospitalization for untreated and uncontrolled hyperten-
sion. The present study is the first to estimate the direct
medical hospital costs of hypertensive inpatients treatment
(including ICD-codes I10 or I10 combined with E75) in
Vietnam. In this study, we both present both mean and
median costs in the relevant table.
Our analysis estimates that the median total cost of in-
patient treatment and care is US$65 per hypertensive
patient per hospital stay. To put this in perspective, the
total health expenditures in Vietnam per capita in 2010
was only US$83 [12]. As costs of inpatient treatment of
hypertension are high, less costly options such as pro-
grams for earlier detection, treatment and subsequent
control may avert these high hospitalization costs. For
example, an earlier study demonstrated that cost of drug
treatment at a community health station was US$9.4/pa-
tient/year for grade 1 hypertension and US$27/patient/
year for grade 2 and 3 hypertension [11]. When compar-
ing those figures to US$53 for hospitalization of uncon-
trolled sole hypertension in this study, the potential
value of early drug treatment over hospitalization of un-
controlled diseases if evident. Hospitalization for uncon-
trolled hypertensive patients was two times and over five
times the costs of drug treatment for grade 2 or 3 and
grade 1 hypertension, respectively. The high cost for in-
patient care for hypertension in Vietnam is consistent
with a previous study in the Philippines, in which the
lowest median hospitalization costs (US$57) were re-
ported for essential or secondary hypertension among all
hypertension-related hospitalization costs [5].
As expected, the costs of the sole hypertensive patients
(US$53) were lower than the costs for the combined hy-
pertensive and lipid patients (US$78). It is quite plausible
Table 2 Direct costs (US$) per hypertensive inpatient by disease classification and cost category























Inpatient days 29.94 (14.97 - 39.92) 24.95 (9.98 - 34.93) 34.93 (24.95 - 44.91) 29.05 (±16.45) 24.86 (±15.94) 36.48 (±14.69) 41.37 40.01 43.14
Drugs 11.67 (4.63 - 39.76) 8.26 (3.69 - 37.02) 16.13 (8.47 - 51.47) 23.85 (±25.4) 21.24 (±25.26) 28.45 (±25.12) 33.96 34.19 33.65
Tests 13.00 (6.89 - 19.24) 11.56 (5.62 - 15.76) 13.69 (7.81 - 25.76) 15.84 (±13.88) 14.49 (±13.46) 18.22 (±14.37) 22.55 23.33 21.54
Others 1.23 (0.84 - 1.68) 1.17 (0.82 - 1.56) 1.41 (0.85 - 1.83) 1.49 (±2.26) 1.53 (±2.79) 1.41 (±0.6) 2.12 2.47 1.67





















Figure 1 Estimates of base case and scenario analyses for direct costs of hypertensive inpatients in Vietnam. Notes: Scenario 1: 1%
discounting for capital costs. Scenario 2: 5% discounting for capital costs. Scenario 3: Adding a 5% furniture cost to total capital costs. Scenario 4:
Using laboratory test charges instead of cost prices. Scenario 5: 5% discounting for capital costs and adding a 5% furniture cost to total capital
cost. Scenario 6: 5% discounting for capital costs and using laboratory test charges. Scenario 7: 1% discounting for capital costs and adding a 5%
furniture cost to total capital costs. Scenario 8: 1% discounting for capital costs and using laboratory test charges. Scenario 9: Adding a 5%
furniture cost to total capital costs and using laboratory test charges. Scenario 10: 1% discounting for capital cost, adding a 5% furniture cost to
total capital costs and using laboratory test charges. Scenario 11: 5% discounting for capital cost, adding a 5% furniture cost to total capital costs
and using laboratory test charges. Scenario 12: Separating out costs resulting from diagnosing and treating comorbid diseases.
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due to increases in length of stay, compared to a single
disease condition. In this study, median lengths of stay
were 5 and 7 days for I10 and I10 combined with E75, re-
spectively. These inpatients days were associated with high
costs, representing 41% of the total cost. This finding dif-
fers from the study conducted in the Philippines, which
reported medication costs (34% of the total) as the highest
cost component [5]. However, this comparison between
Vietnam and the Philippines may only have limited valid-
ity due to differences in perspectives and methods to esti-
mate costs, differences in drug prices, and differences in
overall investments in health care and health-care systems
between both countries.
In this study, the number of inpatient days for sole-
hypertensive patients was 5 days. These patients may
have undetected and uncontrolled hypertension and
now requires hospitalization to be diagnosed for primary
or secondary hypertension. In addition, there is no am-
bulatory blood-pressure monitoring service available in
the community. Patients must be admitted to a hospital
for diagnosis. As an alternative to expensive hospital
care, community level health services may serve as a
cheaper option, but these centers need to be strengthened
to enable blood-pressure monitoring for the broader
population.
The present findings must be interpreted in the con-
text of potential limitations. Firstly, the study was con-
ducted in one hospital, which may not be representative
hospitals across the country. However, it is a govern-
mental and not-for-profit hospital that is potentiallysimilar to other hospitals regarding governmental invest-
ments in hospital beds [17]. Thus, inpatient-day costs
may be extrapolated to other hospitals, which have simi-
lar investments with the explicit notice that costs of each
patient may be different as different care needs exist
among patients. Secondly, we could not identify the
grade of hypertension nor the exact type of sphingolipid
metabolism or lipid storage disorder so the association
between costs and seriousness of disease could not be
made at such detailed level, or even at the level of exact
blood pressure values. However, others have suggested
that the level of systolic or diastolic blood pressure is
not a valid predictor for cost outcomes [20]. Thirdly, we
may have excluded some patients who were sole hyper-
tensive or had combined lipid disorder but were not
identified with I10 (combined) codes. Fourthly and con-
versely, there may be patients who were miscoded for
I10 or E75, and thus incorrectly included in our analysis.
We cannot estimate the size of this problem. However, it
is reasonable to assume that it is small and likely ran-
dom and would therefore not introduce specific biases
in our study. Furthermore, we calculated tests’ costs
based on the assumption the that total numbers for each
test in quarters 3 and 4 would be equal to the total num-
bers in quarters 1 and 2, with lack of data for the whole
year. Notably, some seasonality in testing may have some
influence on our results. Finally, while available data did
not allow for measurement of cost per day at each de-
partment for each disease as well as detailed admission
costs and costs of examination at specialist department,
we did perform specific analyses assuming price weights,
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However, this implies that the estimate may be artifi-
cially under- or overestimate costs.Conclusions
In comparison to annual medication treatment at a com-
munity health station for hypertension and total health
expenditure per capita in Vietnam, the costs of hos-
pitalization of hypertensive patients is high. The main
driver of the costs is related to inpatient days rather than
to treatment, laboratory or other cost categories. Our
findings have important implications for health policies.
Costs of treatment for hypertension and combined dis-
orders of sphingolipid metabolism and other lipid stor-
age disorders in this study could become the reference
case for reimbursement when health insurance compan-
ies apply reimbursement by fee for diagnostic-related
groups. The findings in this study, particularly the high
cost of hospitalization for untreated and uncontrolled
hypertension, justify increasing current expenditures by
the Vietnamese health-care sector on effective interven-
tions to control high blood pressure, which may produce
savings to the health care budget by preventing expen-
sive complications.Additional file
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